Edward L Nelson MD FACP

Hematologic Oncology, Complementary and Integrative

Professor Medicine and Prof. Mol Biol & Biochem, Vice Chair for Academic Affairs, Department of Medicine. NCI designated Chao Family Comprehensive Cancer Center, Assoc. Dir. CRETC School of Medicine, UC Irvine

Join to view full profile

UCI Medical Center101 The City Drive SouthOrange, CA 92868
Phone+1 714-456-5153
Fax+1 714-456-2242

Dr. Nelson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nelson's full profile Already have an account?

Summary

Dr. Edward L Nelson is a physician scientist and an oncologist in Orange, CA. and is affiliated with UCI Medical Center. He received his medical degree from Oregon Health & Science University School of Medicine and has been in practice 31 years. He specializes in hematologic oncology and integrative oncology and is experienced in, hematologic oncology with a primary focus on lymphoma, both Hodgkin's and non-Hodgkin's.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Allergy and Immunology, 1992 - 1995
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1989 - 1992
University of Rochester Medical CenterResidency, Internal Medicine, 1986 - 1989
Oregon Health and Science University School of MedicineClass of 1986, MD, Cum Laude
Willamette UniversityBS, Chemistry, 1973 - 1977

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1989 - 2026
MD State Medical License 1995 - 2001
NY State Medical License 1987 - 1999
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

OCMA Physician of Excellence 2007-2024
America’s Top Doctors Castle Connelly, 2012-2024
Medical Honoree for Education, Mentorship, and support of ACS ACS Southern California Chapter, 2019

Publications & Presentations

PubMed

Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency.
Enya Li, Nina Butkovich, Jo A Tucker, Edward L Nelson, Szu-Wen Wang
Biomaterials. 2026-10-01
R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma.
Benjamin J Lee, Shawn P Griffin, Jean Doh, Anthony Quach, Yujiao Sun
Clinical Lymphoma, Myeloma & Leukemia. 2025-12-01
Improving central line-associated bloodstream infection prevention practices in oncology clinic patients: mobile-app based surveillance & response.
Hiroki Saito, Shereen Nourollahi, Mohamad N Alsharif, Bardia Bahadori, Tom Tjoa
Infection Control and Hospital Epidemiology. 2025-05-01

Journal Articles

HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
Nelson, E.L., Clinical Investigation (2014), 4(9), 791–823
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Nelson, E.L., Clinical Investigation (2014), 4(8), 705–728
HER2/neu: An increasingly important therapeutic target: Part 1 Basic Biology & Therapeutic Armamentarium
Nelson E.L, Clin. Invest. (2014) 4(7),649–671

Books/Book Chapters

Handbook of Cancer Vaccines in Cancer Drug and Discovery Series.
Chapter: Alphaviral-based Strategies for Immmunotherapy of Cancer
Edward L. Nelson & Jonathan SmithEditors: Lyerly, M. Morse and T. Clay.Human Press

Abstracts/Posters

Assessing quality of life and biomarkers in cervical cancer survivors.
Biegler, K., Wenzel, L., Osann, K., McClure, L., Monk, B., & Nelson, E, International Society of Quality of Life Research meeting, New Orleans, LA
The Venezuelan Equine Encephalitis Replicon Vector System Has Selective and Restricted Tropism for a Sub-set of Immature Myeloid Dendritic Cells.
Nishimoto KP. Laust AK, Nelson EL, ISBTc Annual Meeting, Los Angeles, CA
Stress, Immunity, and Cervical Cancer: Quality of Life Associated Immune Modulation.
Nelson EL, Wenzel LB, Osann K, Dogan-Ates A, Laust AK, Nishimoto KP, Chantana N, Reina-Patton A, duPont N; Monk BJ, Chicz-Demet A, Journal of Immunotherapy. 29(6):668, ISBTc Annual Meeting, Los Angeles, CA

Lectures

The Micropallet Array (aka Bio-Pod) Technology: An Ongoing Translational Saga.
Chao Family Comprehensive Cancer Center Conference, Rancho Mirage, CA
Finding Your Niche.
Annual Meeting Society for Immunotherapy of Cancer, Bethesda, MD
Hidden Jewel of Our Community.
Orange County Hispanic Chamber of Commerce, UCI and UCIMC, Orange CA

Other

A Case Report of a 33 Year Old Female with Concomitant Sinus Histiocytosis with Massive Lymphadenopathy (Rosai-Dorfman Disease) and Diffuse Large B-Cell Lymphoma.
Moore J.C., Zhao X. Nelson E.L, Journal of Medical Case Reports 2008, 2:70
http://www.jmedicalcasereports.com/content/2/1/70
A question of attitude The link between chronic stress and a marker of old age is being disentangled.
Nelson EL, The Economist
http://www.economist.com/node/18526881
HER 2/neu Target Antigen and Use of Same to Stimulate an Immune Response.
Nelson EL, U.S. Patent No. 7,446,185